Prognostic Importance of S-phase Fraction in Soft-Tissue Sarcoma
Author Information
Author(s): P Gustafson, M Ferno, M Akerman, B Baldetorp, H Willen, D Killander, A Rydholm
Primary Institution: University Hospital, Lund, Sweden
Hypothesis
The S-phase fraction (SPF) can provide prognostic information in patients with soft-tissue sarcoma.
Conclusion
The S-phase fraction is a valuable prognostic factor for metastasis-free survival in soft-tissue sarcoma patients.
Supporting Evidence
- Patients with high SPF had a significantly lower 5-year metastasis-free survival rate compared to those with low SPF.
- SPF was independently prognostic for metastasis when combined with other factors like tumor size and necrosis.
- Low SPF patients had a prolonged clinical course regarding metastases and local recurrence.
Takeaway
Doctors can use a test called S-phase fraction to help predict how well patients with soft-tissue sarcoma will do after treatment.
Methodology
Flow cytometric DNA analysis was performed on paraffin-embedded material from patients with soft-tissue sarcoma to determine the S-phase fraction.
Potential Biases
The study may have selection bias as it only included patients whose SPF could be calculated.
Limitations
SPF could not be calculated in 100 of the 260 patients, which may limit the method's usefulness.
Participant Demographics
The median age of participants was 62 years, with a range from 18 to 87 years.
Statistical Information
P-Value
<0.0001
Confidence Interval
95% CI 0.92-1.0
Statistical Significance
p<0.0001
Want to read the original?
Access the complete publication on the publisher's website